FDA sets September review date for Calliditas’ rare kidney disease drugCalliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA Share XFDA sets September review date for Calliditas’ rare kidney disease drughttps://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/
Calliditas eyes 2022 approval in EU for rare kidney disease drug NefeconCalliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), Share XCalliditas eyes 2022 approval in EU for rare kidney disease drug Nefeconhttps://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/
Calliditas plans to file rare kidney disease drug Nefecon after phase 3 successSwedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next Share XCalliditas plans to file rare kidney disease drug Nefecon after phase 3 successhttps://pharmaphorum.com/news/calliditas-plans-to-file-rare-disease-drug-nefecon-after-phase-3-success/
Calliditas hits $90m jackpot as biotech IPO craze continuesSwedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease Share XCalliditas hits $90m jackpot as biotech IPO craze continueshttps://pharmaphorum.com/news/calliditas-hits-90m-jackpot-as-biotech-ipo-craze-continues/
European regulators grant fast path to market for Calliditas’ rare kidney disease drugEuropean regulators have granted a fast path to market for Calliditas Therapeutics’ potential rare kidney disease drug, Nefecon, Share XEuropean regulators grant fast path to market for Calliditas’ rare kidney disease drughttps://pharmaphorum.com/news/european-grant-fast-path-to-market-for-calliditas-rare-kidney-disease-drug/
FDA agrees to downsized trial for Calliditas’ rare disease drugThe FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, Share XFDA agrees to downsized trial for Calliditas’ rare disease drughttps://pharmaphorum.com/news/fda-agrees-to-downsized-trial-for-calliditas-rare-disease-drug/
